Somatropin · Genotropin, Humatrope

What is Somatropin?

Somatropin is a recombinant human growth hormone that binds dimeric growth hormone receptors on target tissue cells, triggering IGF-1 and related protein induction and stimulating skeletal growth. It is used in growth disorders in children and in adults with growth hormone deficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Genotropin, Humatrope, Omnitrope, Zomacton, CB-311, LY-137998

Drug type

Recombinant protein

Targets

growth hormone receptor (GHR)

Mechanism

Agonist of growth hormone receptor (GHR)

Pathways

IGF-1 signaling, chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, lipolysis

Therapy area

Endocrine

Developer

Lilly

In trials of

ASND

FDA status

Approved as Genotropin, Humatrope, Omnitrope (October 16, 1986), BLA019640 · FDA label

UNII

NQX9KB6PCL

✅ FDA-approved uses

• Growth failure due to inadequate secretion of endogenous growth hormone (Humatrope)
• Turner syndrome short stature (Humatrope)
• Idiopathic short stature (Humatrope)
• SHOX deficiency short stature (Humatrope)
• Short stature born small for gestational age (Humatrope)
• Adult growth hormone deficiency (Humatrope)
• Growth failure due to growth hormone deficiency (Genotropin)
• Prader-Willi syndrome (Genotropin)

From the indications section of the FDA label (version of Aug 20, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Endocrine System DiseasesGrowth Hormone Deficiency, PediatrichGH (Human Growth Hormone)HormonesPituitary Diseases

Other drugs acting on GHR

Sources

• FDA Purple Book
• FDA label (DailyMed)
• FDA label Humatrope (2026-08-20), indications
• FDA label Genotropin (2026-08-04), indications
• FDA label Zomacton (2026-04-20), indications
• FDA label Omnitrope (2025-07-10), indications
• ClinicalTrials.gov NCT02781727

Updated Oct 11, 2026.